BGMSP stock · MSFT stock · Lician Pro · $19.99/mo or $149/yr

BGMSP vs MSFT

Bio Green Med Solution (BGMSP) versus Microsoft Corporation (MSFT) — a side-by-side from cached financials, not a winner call.

Bio Green Med Solution (BGMSP) preferred stock listed on NASDAQ.

Microsoft Corporation (MSFT) is a software - infrastructure company listed on US. It is led by Satya Nadella.

Latest reported BGMSP revenue for 2025-12-31 was $0. Net income was -$3.0M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31.

Latest reported MSFT revenue for 2026-06-30 was $331.84B. Net income was $133.75B. Revenue was up 17.8% from 2025-06-30 to 2026-06-30. MSFT currently screens at market cap $3.71T.

MSFT currently screens at market cap $3.71T.

Not investment advice. Open the BGMSP and MSFT stock pages for the full models.

Basic comparison

Price, market cap, and trailing P/E stay on this page.

BGMSP vs MSFT
MetricBGMSPMSFT
Price$2.41$529.05
Market cap—$3.71T
Trailing P/E——

Deeper peer metrics

Net income and multi-year revenue growth are the peek. More peer metrics open below. This block stops at the labels.

More peer metrics

Operating margin, EPS, free cash flow, and gross margin are on Pro.

Unlock deeper peer metrics

BGMSP vs MSFT comparison FAQ

What is BGMSP's latest revenue?

Latest reported BGMSP revenue for 2025-12-31 was $0.

What is MSFT's market cap?

Microsoft Corporation (MSFT) currently screens at market cap $3.71T.

What is BGMSP's net income?

Net income was -$3.0M for Bio Green Med Solution (BGMSP).

What is MSFT's latest revenue?

Latest reported MSFT revenue for 2026-06-30 was $331.84B.

How did BGMSP revenue change on this page?

Revenue was down 100.0% from 2024-12-31 to 2025-12-31.

What is MSFT's net income?

Net income was $133.75B for Microsoft Corporation (MSFT).

How did MSFT revenue change on this page?

Revenue was up 17.8% from 2025-06-30 to 2026-06-30.

Where is the BGMSP vs MSFT comparison listed?

The cached BGMSP vs MSFT comparison is listed at https://lician.com/compare/bgmsp-vs-msft.

Not investment advice.

Popular Stock Comparisons